Skip navigation

Vaccine Production:

Potential Engineering Approaches to a Pandemic

Home :: Speakers :: Alan R. Shaw

Conference Speaker

Alan R. Shaw, PhD
President and CEO, VaxInnate

Alan R. Shaw, Ph.D. is currently the President and Chief Executive Officer of VaxInnate, a biotechnology company making vaccines that incorporate activators of the innate immune system. Prior to this, he was the Executive Director of Virus & Cell Biology at Merck Research Laboratories, and was responsible for all aspects of live virus vaccine research, as well as technical aspects of development and production. He was also responsible for research and early development of recombinant protein-based vaccines. Dr. Shaw has been instrumental in the development of Varivax, ProQuad®, RotaTeq®, Gardasil®, the zoster vaccine Zostavax®, as well as numerous early-stage experimental vaccines. Prior to joining Merck, Dr. Shaw worked on vaccines for hepatitis B and Plasmodium falciparum as well as cytokines, cell trafficking and natural inhibitors of interleukin-1 at Biogen, SA in Geneva, Switzerland. Dr. Shaw received a B.A. from Rice University, a M.S. in molecular biology from the University of Texas at Dallas, and a Ph.D. in molecular biology at the Medical College of Ohio. He held post doctoral fellowships at the International Institute of Cellular Pathology in Brussels and The Rockefeller University. Dr. Shaw is the past Chairman of the International Federation of Pharmaceutical Manufacturers Association Biologicals Committee and a part time member of the faculty at Temple University.

Vaccine Production: Potential Engineering Approaches to a Pandemic
April 10-11, 2006

If you can read this message you probably are using a browser that is out dated.
Your internet browsing experience will improve by simply upgrading your browser
to the current version.